Advocacy Resources on the 340B Program

ADAP Advocacy has made available the following resources for more effective patient advocacy, calling for patient-centric reforms to the 340B Drug Pricing Program:

Reports

 Is the 340B Drug Pricing Program the Next ‘Too Big to Fail’? (March 2025)

The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities – Supplemental Report (February 2025)

Patient Medical Debt: Findings from Quantitative Surveying of Patients in the United States (April 2025)

The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities
(July 2024)

340B Program Reform: The Issues Spurring Discussion, Stakeholder Stances and Possible Resolutions (February 2019)

Infographics

340B Too Big to Fail: Executive Compensation – Part 2 (November 2025)

340B Too Big to Fail: Executive Compensation – Part 1 (November 2025)

340B Drug Pricing Program: Too Big To Fail? Medical Debt – Part 2 (September 2025)

340B Drug Pricing Program: Too Big To Fail? Medical Debt – Part 1 (September 2024)

340B Drug Pricing Program: Too Big To Fail? What are Hospitals Hiding? (July 2025)

340B Drug Pricing Program: Too Big To Fail? (June 2025)

340B Drug Pricing Program: Charity Care Declines & Medical Debt Explodes (November 2024)

340B Drug Pricing Program: Charity Care Declines (November 2024)

340B Drug Pricing Program: Medical Debt Explodes (November 2024)

Videos

Scroll to Top